A 6-amino-acid peptide (Ac-EEMQRR-NH2) marketed as a topical 'Botox alternative.' It is designed to inhibit SNARE complex assembly at the neuromuscular junction, reducing the intensity of muscle contractions that cause expression lines. The most commercially successful cosmetic peptide targeting wrinkles of muscular origin.
Argireline (acetyl hexapeptide-3, Ac-EEMQRR-NH2) was developed by Lipotec (now part of Lubrizol) as a topical peptide that could reduce expression lines (forehead wrinkles, crow's feet) through a mechanism inspired by botulinum toxin — but without needles. It was introduced in 2002 and quickly became one of the most marketed cosmetic peptides.
The peptide's sequence is derived from a portion of SNAP-25 (synaptosome-associated protein of 25 kDa), one of three proteins in the SNARE complex required for neurotransmitter release at the neuromuscular junction. By competing with native SNAP-25, Argireline partially inhibits SNARE assembly, reducing acetylcholine release and thus the intensity of facial muscle contractions.
At the neuromuscular junction, acetylcholine-containing vesicles fuse with the presynaptic membrane through the SNARE complex — a molecular machine consisting of SNAP-25, syntaxin-1, and VAMP/synaptobrevin. Botulinum toxin (Botox) works by proteolytically cleaving SNAP-25, permanently blocking vesicle fusion until new SNAP-25 is synthesized. Argireline takes a gentler approach: it competes with native SNAP-25 for SNARE complex assembly, reducing (but not eliminating) neurotransmitter release.
| Pathway | Effect | Significance |
|---|---|---|
| SNARE competition | Competes with SNAP-25 for SNARE complex incorporation | Reduces but does not eliminate vesicle fusion |
| Partial NMJ inhibition | Decreases acetylcholine release at facial neuromuscular junctions | Softens muscle contraction intensity without paralysis |
| Expression line reduction | Reduced contraction force decreases skin folding | Prevents deepening of dynamic wrinkles over time |
| No systemic effects | Topical delivery limits activity to superficial tissues | Much safer than injected Botox but weaker effect |
| Study | Design | Findings | Level |
|---|---|---|---|
| Wrinkle reduction | Double-blind, n=60, 30 days | 10% Argireline solution reduced wrinkle depth by up to 30% vs placebo (Lipotec study) | Level II |
| Mechanism confirmation | In vitro, neuroendocrine cells | Argireline reduced catecholamine release by 30-40% in a dose-dependent manner | Preclinical |
| Long-term use | Clinical study, 28 days | Continued improvement with daily use; effects reversible upon discontinuation | Level II-III |
Excellent topical safety: Non-toxic, non-irritating, non-sensitizing in clinical and safety testing.
No paralysis risk: Unlike Botox, Argireline only partially inhibits muscle contraction. Cannot cause facial paralysis or drooping.
Weaker than Botox: The trade-off for safety: Argireline produces modest wrinkle reduction (30%) compared to Botox (80-100%). They address different market segments.
| Jurisdiction | Status |
|---|---|
| FDA | Cosmetic ingredient. Not regulated as a drug. |
| EU | Approved cosmetic ingredient (CosIng) |
| INCI | Acetyl Hexapeptide-3 |
| Feature | Argireline | Botulinum Toxin (Botox) |
|---|---|---|
| Mechanism | Competes with SNAP-25 (reversible) | Cleaves SNAP-25 (semi-permanent) |
| Route | Topical cream/serum | Injection into muscle |
| Efficacy | ~30% wrinkle reduction | ~80-100% wrinkle reduction |
| Onset | 2-4 weeks | 3-7 days |
| Duration | Requires continuous use | 3-6 months per treatment |
| Safety | No paralysis risk | Risk of ptosis, asymmetry |
| Cost | $20-80 per product | $300-600 per treatment |
| Prescription | Not required | Required |